News

Zacks Investment Research on MSN18h
Novo Nordisk Q1 Earnings Match Estimates, Revenues Rise Y/Y, Stock Up
Novo Nordisk A/S NVO reported first-quarter 2025 earnings of 92 cents per American Depositary Receipt (ADR), which matched ...
Mayo Clinic Study Uses Phenomix AI Algorithm to Predict GLP-1 Side Effects, Advancing Personalized Obesity Care and Drug Development
Phenomix Sciences (Phenomix), the first commercial precision obesity medicine biotechnology company, in partnership with Mayo ...
The Cardiology Advisor1d
Tirzepatide Dose Escalation Slower in Real-World vs Trials in Obesity Minus T2D
Tirzapetide dose escalation schedules were slower in the real-world than clinical settings among individuals with obesity without T2D.
Nanexa AB: Nanexa publishes interim report for January-March 2025
Very interesting data from the latest study and successful share issue. Significant events during the first quarter of 2025In January, Nanexa announced that the company had decided to carry out a dire ...